Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis

International Archives of Allergy and Immunology
Wolfgang R SperrP Valent

Abstract

Systemic mastocytosis (SM) is a myeloproliferative disease affecting multipotent and/or mast cell-committed hematopoietic progenitor cells. In a significant subgroup of patients (10-35%), an associated clonal hematologic non-mast cell lineage disorder (AHNMD) occurs. These AHNMDs can be classified according to recently established WHO criteria. Most AHNMDs resemble myeloid malignancies such as acute myeloid leukemia, myeloproliferative disorders or myelodysplastic syndromes. In only a few cases, lymphoproliferative disorders are diagnosed. Patients with SM-AHNMD have a less favorable prognosis concerning survival when compared to indolent SM. No general guidelines for the treatment of patients with SM-AHNMD have been established so far. A reasonable straightforward approach may be to treat the AHNMD in those patients in the same way as if no coexisting SM exists.

Citations

Aug 12, 2009·Journal of Hematopathology·Sheeja T PullarkatRussell K Brynes
Dec 17, 2003·Current Opinion in Hematology·Ayalew Tefferi, Animesh Pardanani
Jul 24, 2008·Journal of Gastroenterology·Yukihiko Kitamura
Nov 28, 2012·Wiener klinische Wochenschrift·Peter ValentKarin Hartmann
Apr 22, 2014·Immunology and Allergy Clinics of North America·Cem Akin, Peter Valent
Mar 30, 2010·La Revue de médecine interne·J-B ArletL Chiche
Apr 25, 2007·The Journal of Allergy and Clinical Immunology·Alexandra BöhmPeter Valent
Jul 17, 2010·Pathology·Catherine Fong, Michael Tong
Jul 9, 2004·The Journal of Allergy and Clinical Immunology·Luis EscribanoAlberto Orfao
May 4, 2004·Immunology and Allergy Clinics of North America·Knut Brockow
Aug 23, 2005·Leukemia Research·Hermine AgisHans-Peter Horny
Apr 18, 2015·Journal of Hematology & Oncology·Axel SchulenburgPeter Valent
Sep 22, 2010·Blood·Peter ValentCem Akin
Dec 17, 2019·International Journal of Laboratory Hematology·Valentina Fabiola Ilenia SangiorgioAttilio Orazi
Nov 15, 2011·American Journal of Hematology·Celalettin UstunTracy I George
Jul 12, 2012·Expert Review of Hematology·Wolfgang R Sperr, Peter Valent
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wolfgang R SperrPeter Valent
May 5, 2021·Current Hematologic Malignancy Reports·Siba El HusseinSanam Loghavi
Mar 26, 2004·Gastroentérologie Clinique Et Biologique·Dominique WendumJean-François Flejou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.